Published in Semin Oncol on December 01, 2010
p53 suppresses carcinoma progression by inhibiting mTOR pathway activation. Oncogene (2014) 0.94
Sporadic medullary thyroid carcinoma with a pedunculated intraluminal internal jugular vein recurrence: A case report and literature review. Int J Surg Case Rep (2011) 0.89
Octreotide-functionalized and resveratrol-loaded unimolecular micelles for targeted neuroendocrine cancer therapy. Nanoscale (2013) 0.84
KE108-conjugated unimolecular micelles loaded with a novel HDAC inhibitor thailandepsin-A for targeted neuroendocrine cancer therapy. Biomaterials (2016) 0.82
MK-2206 causes growth suppression and reduces neuroendocrine tumor marker production in medullary thyroid cancer through Akt inhibition. Ann Surg Oncol (2013) 0.81
Reduced USP39 expression inhibits malignant proliferation of medullary thyroid carcinoma in vitro. World J Surg Oncol (2015) 0.77
PET Imaging in Recurrent Medullary Thyroid Carcinoma. Int J Mol Imaging (2012) 0.77
(18)F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography for Other Thyroid Cancers: Medullary, Anaplastic, Lymphoma and So Forth. Mol Imaging Radionucl Ther (2017) 0.75
Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. Surgery (2016) 0.75
Treating medullary thyroid carcinoma in a tertiary center. Current trends and review of the literature. Hippokratia (2014) 0.75
Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid (2009) 10.20
Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol (2010) 2.96
Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking. J Biol Chem (2004) 2.18
Sentinel lymph node biopsy in patients with thin melanoma. Arch Dermatol (2003) 2.11
Neuroendocrine tumors. J Natl Compr Canc Netw (2012) 1.91
Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators. Am J Physiol Endocrinol Metab (2002) 1.82
Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery (2002) 1.70
Pheochromocytoma penetrance varies by RET mutation in MEN 2A. Surgery (2007) 1.64
Exclusion of malignancy in thyroid nodules with indeterminate fine-needle aspiration cytology after negative 18F-fluorodeoxyglucose positron emission tomography: interim analysis. World J Surg (2010) 1.57
Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw (2015) 1.51
ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol (2006) 1.41
Biochemical cure after reoperations for medullary thyroid carcinoma: a meta-analysis. Ann Surg Oncol (2014) 1.39
Needle biopsy of incidentally discovered adrenal masses is rarely informative and potentially hazardous. Surgery (2007) 1.13
Gastrointestinal manifestations of multiple endocrine neoplasia type 2. Ann Surg (2002) 1.12
Current approaches to medullary thyroid carcinoma, sporadic and familial. J Surg Oncol (2006) 1.11
Risk factors affecting operative approach, conversion, and morbidity for adrenalectomy: a single-institution series of 402 patients. Surg Endosc (2013) 1.06
Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer. Ann Surg Oncol (2007) 1.05
Outcomes of resection of extra-adrenal pheochromocytomas/paragangliomas in the laparoscopic era: a comparison with adrenal pheochromocytoma. Surg Endosc (2012) 1.04
Contralateral papillary thyroid cancer at completion thyroidectomy has no impact on recurrence or survival after radioiodine treatment. Surgery (2006) 1.02
Sporadic and familial medullary thyroid carcinoma: state of the art. Surg Clin North Am (2009) 1.01
Expression profiles provide insights into early malignant potential and skeletal abnormalities in multiple endocrine neoplasia type 2B syndrome tumors. Cancer Res (2004) 1.00
Lymph node metastases in differentiated thyroid cancer under 2 cm. Surgery (2006) 0.95
Metastatic disease to the breast: the Washington University experience. World J Surg Oncol (2007) 0.95
Prognostic factors in patients with well-differentiated thyroid cancer presenting with pulmonary metastasis. Cancer Biother Radiopharm (2008) 0.95
Adrenalectomy for familial pheochromocytoma in the laparoscopic era. Ann Surg (2002) 0.93
Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes. J Surg Oncol (2005) 0.92
Long-term functionality of cryopreserved parathyroid autografts: a 13-year prospective analysis. Surgery (2005) 0.91
Adrenal ganglioneuromas in children with multiple endocrine neoplasia type 2: a report of two cases. J Clin Endocrinol Metab (2005) 0.90
Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases. Clin Cancer Res (2012) 0.90
ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. Ann Surg Oncol (2006) 0.88
Medullary thyroid cancer. Surg Oncol Clin N Am (2006) 0.87
Adrenal myelolipoma: operative indications and outcomes. J Laparoendosc Adv Surg Tech A (2013) 0.85
Preparation of patients with thyroid cancer for 131I scintigraphy or therapy by 1-3 weeks of thyroxine discontinuation. J Nucl Med (2004) 0.83
Medullary thyroid carcinoma: management of lymph node metastases. Curr Treat Options Oncol (2005) 0.83
Multiple endocrine neoplasia type 2: clinical manifestations and management. Cancer Treat Res (2010) 0.82
Treatment approach, surveillance, and outcome of well-differentiated thyroid cancer in childhood and adolescence. Thyroid (2014) 0.81
The role of surgery in cancer prevention. Curr Probl Surg (2010) 0.81
Pheochromocytoma in an 8-year-old patient with multiple endocrine neoplasia type 2A: implications for screening. J Surg Oncol (2013) 0.79
Ultrasound facilitates minimally invasive parathyroidectomy in patients lacking definitive localization from preoperative sestamibi scan. Am J Surg (2007) 0.79
Outpatient minimally invasive parathyroidectomy using local/regional anesthesia: a safe and effective operative approach for selected patients. Surgery (2005) 0.79
Hereditary medullary thyroid carcinoma in patients greater than 50 years old. Surgery (2004) 0.78
Anaplastic Thyroid Carcinoma, Version 2.2015. J Natl Compr Canc Netw (2015) 0.78
The RET Protooncogene. Cancer Treat Res (2010) 0.78
Medullary thyroid cancer: medical management and follow-up. Curr Treat Options Oncol (2005) 0.77
RET proto-oncogene testing in infants presenting with Hirschsprung disease identifies 2 new multiple endocrine neoplasia 2A kindreds. J Pediatr Surg (2008) 0.76
Management of cervical nodal metastasis detected on I-131 scintigraphy after initial surgery of well-differentiated thyroid carcinoma. Surgery (2010) 0.76
A novel missense mutation in the MEN1 gene in a patient with multiple endocrine neoplasia type 1. Endocr Pract (2011) 0.76
Hereditary thyroid cancer syndromes and genetic testing. J Surg Oncol (2014) 0.75